Alveo empowers better outcomes in human, animal and environmental health by making early pathogen detection accessible at the point-of-need.

Shaun Holt serves as Chairman of the Board and Chief Executive Officer of Alveo Technologies. Previously, Shaun served as Chief Operating Officer of Atonarp, Inc., a Celesta Capital-backed optical- and mass-spectrometry instrumentation company. Prior to Atonarp, as Chief Financial Officer for Berkeley Lights, Inc., Shaun led the digital cell biology company through its $205 million initial public offering. In addition, Shaun held numerous finance leadership positions during his seven-year tenure at Illumina throughout its exponential growth phase. He brings more than 20 years of operational and financial leadership experience across various technology and life sciences companies from start-ups to large-capitalization companies. Shaun is an advisor to Celesta Capital and serves on the Board of Directors of Prellis Biologics.

As Alveo’s Chief Business and Strategy Officer, Erik Tyrrell-Knott leads business and market development, sales, partnering and product management efforts, driving the Company’s commercial, partnership and go-to-market strategies. With more than 20 years of experience in strategic business development for medical device and diagnostic companies ranging from start-ups to mature global corporations, Erik most recently served as Vice President of Business Development at Atonarp, Inc., and previously as Head of Business Development for Thermo Fisher Scientific, and previously as Senior Vice President of Business Development and Product Management at Mesa Biotech prior to its acquisition by Thermo Fisher.

Dr. Slava Elagin brings to Alveo more than 20 years of experience in the in vitro diagnostics and medical devices industry. Previously, Slava held senior executive operations and research and development positions with publicly traded and private companies including MiraVista Diagnostics, Meridian Biosciences, EraGen Biosciences and Third Wave Technologies. He has led 15 molecular diagnostic product development projects from product concept through U.S. Food & Drug Administration clearances and commercialization and is the author on 12 U.S. patents and three global patents for molecular assays and diagnostics.

Angie Aquino-Sales serves as Senior Director of People & Culture at Alveo Technologies, where she is focused on human resources strategic planning and organizational design, building HR functions, and designing talent programs for leader and employee development.

Prior to joining Alveo, Angie served at Prologis as a Senior Human Resources Business Partner, at OptiScan Biomedical as Head of HR, and at Tripping.com as Director of HR. Angie has experience working in start-ups and small businesses in a variety of industries. She has held related roles in large organizations including Kaiser Permanente, Blue Shield of California, and McKesson.

Helen Belcastro brings over 20 years of experience in cross-functional program and project management in the medical device and biotechnology arenas to her role as Vice President, Portfolio Planning and Program Management at Alveo Technologies. Previously, she applied her program management leadership to the digital transformation of molecular diagnostics at Atonarp, helping to improve clinical outcomes and enhance the patient experience. Prior to Atonarp, Helen built her extensive experience managing complex product development projects at all stages from concept through product release through her work at companies including ViewRay, Inc., VytronUS, Intuitive Surgical, Novartis Vaccines and Diagnostics, and Boston Scientific.

Lisa Charter is an accomplished leader in the field of regulatory affairs, leveraging over 25 years of expertise across various domains including therapeutic drug monitoring, toxicology, anatomical pathology, hematology, allergy diagnostics, and direct-to-consumer genetics. Currently serving as Vice President of Regulatory Affairs at Alveo Technologies, Lisa plays a pivotal role in steering regulatory strategies and ensuring regulatory compliance.

‍

With a rich background in medical device regulation, Lisa's journey encompasses pivotal roles at esteemed organizations such as Atonarp, 23andMe, Hitachi Chemical Diagnostics, and ThermoFisher Scientific. Notably, at 23andMe, she spearheaded groundbreaking initiatives securing multiple first-of-their-kind de novo authorizations and 510(k) clearances for direct-to-consumer genetic tests.

‍

Beyond her professional commitments, Lisa remains deeply engaged in advancing regulatory standards within the industry. Her dedication extends to her current position on the Board of Directors for the Association of Medical Diagnostics Manufacturers (AMDM), where she actively contributes to shaping educational resources for regulatory professionals, facilitating knowledge exchange on submission and compliance requirements.

John, a seasoned Manufacturing Operations Leader, spans small startups to industry giants like Flextronics, Mars Petcare, and Tesla Motors, showcasing expertise in management, manufacturing, and logistics. Excelling in building capabilities, crafting efficient supply chains, and fostering effective organizations, John's hands-on approach and strategic mindset have been instrumental in both internal and external manufacturing. His proven track record solidifies him as a valuable and respected leader in manufacturing operations, with a career defined by impactful contributions to diverse enterprises.

Mary McFillin is a senior global product marketing manager with extensive experience in the point-of-care diagnostics industry, leading strategy, development and support of in vitro diagnostics medical devices throughout the product life cycle. As a senior product management executive, Mary leads Alveo’s strategic marketing and target market development. She joins Alveo from Thermo Fisher Scientific, Rapid Diagnostic Solutions, where she served as Senior Manager of Product Management. Previously, she held similar positions for Abbott Laboratories and Alere, Inc.